HDAC6 and colorectal carcinoma: Overall, these results indicate that the combined treatment of the chemotherapeutic agent 5-FU with the HDAC6 inhibitor Tubastatin A may prove to be a potential novel curative approach for CRC patients, especially in those cases where the IL-6/STAT3/FRA1 signaling axis is activated.